Collaborative Arrangements and Pending Acquisition - CRISPR Therapeutics AG (Details) - CRISPR Therapeutics |
1 Months Ended | 3 Months Ended | |
---|---|---|---|
Oct. 31, 2016
USD ($)
|
Oct. 31, 2015
USD ($)
target
|
Jun. 30, 2016
USD ($)
|
|
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Right to license, number of targets (up to) | target | 6 | ||
Up-front payment | $ 75,000,000 | ||
Investment in collaborative partner, pursuant to convertible loan agreement | $ 10,000,000 | 30,000,000 | $ 3,100,000 |
Collaborative funding | 75,000,000 | ||
Collaborative arrangement development and regulatory potential milestone payments maximum | $ 420,000,000 | ||
Prior to marketing approval, time period of notice required to terminate (in days) | 90 days | ||
Subsequent to marketing approval, time period of notice required to terminate (in days) | 270 days |